SA
BCYC

Shilanski & Associates’s Bicycle Therapeutics BCYC Stock Holding History

Shilanski & Associates’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,502
Closed -$241K – 113
2022
Q1 		$241K Buy
5,502
+346
+7% +$16.2K 0.1% 102
2021
Q4 		$314K Buy
+5,156
New +$284K 0.13% 86

Other funds holding BCYC

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Shilanski & Associates's BCYC Position: Q2 2022 in Review

Shilanski & Associates sold out of Bicycle Therapeutics (BCYC) in Q2 2022, closing a stake of 5,502 shares — an estimated $241K sold.

Shilanski & Associates first reported a position in BCYC in Q4 2021 and held it in 2 quarters. The position peaked at $314K in Q4 2021. 81 funds tracked by Wall St. Rank hold BCYC as of Q2 2022.

  • Shilanski & Associates reported no remaining Bicycle Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Shilanski & Associates sold 5,502 Bicycle Therapeutics shares in Q2 2022, an estimated $241K.
  • Shilanski & Associates first reported a position in Bicycle Therapeutics in Q4 2021 and held it in 2 quarters.
  • Shilanski & Associates's Bicycle Therapeutics position peaked at $314K in Q4 2021.
  • 81 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2022.

Based on Shilanski & Associates's 13F filing for Q2 2022, filed 2 Aug 2022.